2,270,550 Shares in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Bought by Point72 Asset Management L.P.

Point72 Asset Management L.P. acquired a new position in shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 2,270,550 shares of the biopharmaceutical company’s stock, valued at approximately $2,316,000.

A number of other large investors also recently added to or reduced their stakes in the stock. E Fund Management Co. Ltd. purchased a new stake in shares of Sangamo Therapeutics during the fourth quarter worth about $25,000. JPMorgan Chase & Co. lifted its stake in Sangamo Therapeutics by 679.5% in the 4th quarter. JPMorgan Chase & Co. now owns 25,000 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 21,793 shares in the last quarter. PNC Financial Services Group Inc. boosted its holdings in Sangamo Therapeutics by 2,319.1% in the 4th quarter. PNC Financial Services Group Inc. now owns 26,078 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 25,000 shares during the last quarter. SBI Securities Co. Ltd. purchased a new stake in Sangamo Therapeutics during the 4th quarter worth approximately $28,000. Finally, Captrust Financial Advisors acquired a new position in shares of Sangamo Therapeutics during the fourth quarter valued at approximately $30,000. 56.93% of the stock is currently owned by institutional investors and hedge funds.

Sangamo Therapeutics Stock Up 0.1%

NASDAQ SGMO opened at $0.50 on Wednesday. The business’s fifty day simple moving average is $0.71 and its 200-day simple moving average is $1.30. The firm has a market cap of $116.37 million, a PE ratio of -0.67 and a beta of 1.46. Sangamo Therapeutics, Inc. has a 52 week low of $0.30 and a 52 week high of $3.18.

Sangamo Therapeutics (NASDAQ:SGMO) last released its quarterly earnings data on Monday, May 12th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.03). Sangamo Therapeutics had a negative return on equity of 264.16% and a negative net margin of 257.87%. The firm had revenue of $6.44 million for the quarter, compared to analyst estimates of $7.90 million. Research analysts expect that Sangamo Therapeutics, Inc. will post -0.46 EPS for the current year.

Analyst Ratings Changes

Several brokerages recently commented on SGMO. HC Wainwright reiterated a “buy” rating and set a $10.00 price target on shares of Sangamo Therapeutics in a research report on Monday, April 7th. Barclays lowered their price target on shares of Sangamo Therapeutics from $9.00 to $5.00 and set an “overweight” rating on the stock in a research report on Wednesday, May 14th. Royal Bank of Canada reiterated a “sector perform” rating and issued a $2.00 price objective on shares of Sangamo Therapeutics in a report on Tuesday, March 18th. Finally, Truist Financial decreased their target price on shares of Sangamo Therapeutics from $7.00 to $5.00 and set a “buy” rating on the stock in a research note on Thursday, January 23rd. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $4.50.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.